Logo
x

Search

Subscribe Now

unresectable

BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or...

  • June 4, 2021
BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for 1L Treatment for Unresectable Malignant Pleural Mesothelioma

BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for 1L Treatment for Unresectable Malignant Pleural Mesothelio...

  • June 3, 2021
ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelioma

ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelio...

  • May 28, 2021
BMS Reports Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC

BMS Reports Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or M...

  • April 9, 2021
Incyte's Pemazyre (pemigatinib) Receives MHLW's Approval for Unresectable Biliary Tract Cancer with a FGFR2 Fusion Gene

Incyte's Pemazyre (pemigatinib) Receives MHLW's Approval for Unresectable Biliary Tract Cancer with a FGFR2 Fusion Gene

  • March 24, 2021
Immunocore's Tebentafusp Receives the US FDA's Breakthrough Therapy Designation for Unresectable or Metastatic Uveal Melanoma

Immunocore's Tebentafusp Receives the US FDA's Breakthrough Therapy Designation for Unresectable or Metastatic Uveal Melanoma

  • February 22, 2021
Elevar Therapeutics Reports the US FDA Acceptance of NDA for Rivoceranib + Camrelizumab as 1L Treatment for Unresectable Hepatocellular Carcinoma

    Elevar Therapeutics Reports the US FDA Acceptance of NDA for Rivoceranib + Camrelizumab as 1L Treatment for Unresectable Hepatocel...

    • July 18, 2023
    AstraZeneca’s Imjudo (tremelimumab) + Imfinzi (durvalumab) Receive the US FDA’s Approval for Unresectable Liver Cancer

      AstraZeneca’s Imjudo (tremelimumab) + Imfinzi (durvalumab) Receive the US FDA’s Approval for Unresectable Liver Cancer

      • October 25, 2022
      Immunocore’s Kimmtrak (tebentafusp) Receives the EC’s Approval for the Treatment of Unresectable or Metastatic Uveal Melanoma

        Immunocore’s Kimmtrak (tebentafusp) Receives the EC’s Approval for the Treatment of Unresectable or Metastatic Uveal Melanoma

        • April 5, 2022
        AstraZeneca Reports Results of Imfinzi + Tremelimumab in P-III HIMALAYA Study for 1L Treatment of Unresectable Liver Cancer

          AstraZeneca Reports Results of Imfinzi + Tremelimumab in P-III HIMALAYA Study for 1L Treatment of Unresectable Liver Cancer

          • October 15, 2021
          BMS Reports Three-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -743 Trial for 1L Treatment of Unresectable Malignant Pleural Mesothelioma

            BMS Reports Three-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -743 Trial for 1L Treatment of Unresect...

            • September 13, 2021
            BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

              BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or...

              • June 4, 2021
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.